ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation

Renal Transplant Rejection Clinical Trial

— ALL-T-COPIES  

Official title:

Alloreactive t Cell Repertoire in Kidney Transplantation Recipients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03422224
• Other study ID #: ALL-T-COPIES
• Status: Recruiting
• Start date: July 1, 2017
• Est. completion date: July 2024

Study information

• Verified date: October 2023
• Source: Medical University of Vienna
• Contact: Constantin N Aschauer, MD
• Phone: 00434040043890
• Email: constantin.aschauer[@]meduniwien.ac.at
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, the investigators will establish a workflow to generate unique patterns of the donor-reactive T cell repertoire using mixed lymphocyte reactions to select alloreactive T cell clones prior to transplantation Tissue infiltrating as well as blood bound T cells will be characterized based on:

1. Identification of donor-specific T cell receptor sequences pre- and post-transplant by in vitro expansion to determine unique patterns

2. Quantification and comparison of donor-specific T cell clones in kidney biopsy and blood samples.

3. Analysis of the TCR repertoire diversities derived from kidney biopsy and blood samples and association of repertoire diversities with the histomorphological phenotype of T cell mediated rejection.

4. Identification of T cell subtypes within the donor-reactive population. The investigators specifically hypothesize that highly expanded donor-reactive T cell clones in both kidney tissue and blood samples at time of indication biopsy are associated with the histological phenotype of acute T cell mediated rejection. The investigators have previously shown that there is a strong correlation between highly expanded tissue-resident T cell clones and the repertoire found in periphery blood samples. To trace and quantify donor reactive T cells the investigators will apply a truly quantitative approach for immune repertoire profiling based on high- throughput sequencing. The investigators ultimate goal is to develop a diagnostic tool to assess alloreactive cellular immunoresponses based on peripheral blood samples.

Description:

Kidney transplant recipients receiving a non lymphodepletional induction therapy at the investigators center will be included in this study.

Alloreactive T cells are defined prior to transplantation via a mixed lymphocyte reaction of donor and recipient PBMC's.

Following transplantation PBMC's will be sampled at management (3 and 12 months) and for-cause biopsies and fifteen patients with histological proven acute T cell mediated rejection will be compared to 15 patients without histopathological signs of alloimmune response in time matched for-cause biopsies.

T cell receptor beta chains of T cells found in the circulation and the allograft biopsy will be sequenced via Next generation sequencing.

Abundance of alloreactive T cells of the overall repertoire pre-and post-transplant and their presence in the allograft will be assessed.

The diversity of the overall repertoire and alloreactive repertoire will be compared between these two groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Kidney transplantation in our center

Exclusion Criteria:

• Donor not evaluated by our center

Related Conditions & MeSH terms

• Alloreactivity
• Immune Repertoire
• Renal Transplant Rejection
• Transplant; Complication, Rejection

Intervention

Diagnostic Test:
• Mixed lymphocyte reaction
Assessment of alloreactive T cell repertoire

Locations

Country	Name	City	State
Austria	Medical university of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rejection	biopsy proven rejection	12 months